Scottish Pro2Kem enters US market from their new base in Chelmsford, Massachusetts

23-Jun-2004 - United Kingdom

Following the successful launch of the AggreKem Protein Aggregation Monitor late last year, and the tremendous interest that has been shown in the technology under development at the company, Pro2Kem are delighted to announce the opening of their first overseas office in Massachusetts.

This major expansion in activity will give the company a base at the heart of one of the major global biotechnology clusters, and will provide a strong springboard into North America for the novel micro-engineered analysis tools under development.

Dr Roger White, founder and CEO of Pro2Kem said: "A strong presence in the North American market has always been key to the ambitious plans we have for the company and our new approach to the development of low cost, high performance bioanalysis tools. The excellent financial, technical, & commercial links we've been able to develop within the Greater Boston Life Science cluster and beyond provides Pro2Kem with a strong platform to assist us to exceed our own aggressive growth targets."

This new Pro2Kem operation will initially be housed at the offices of one of their local partners, the John E Boeing Company, as part of a series of wide ranging agreements made recently between Pro2Kem and key Massachusetts based companies. It will provide pre and post-sales support to the company's rapidly expanding North American customer base. Mark Boeing, President of the John E Boeing Company said: "The Pro2Kem product range provides such a profound cost & performance benefit to our drug research community in new product development, that we anticipate significant activity in our inaugural year."

To support this new operation, an agreement has been signed with Dr Val Livada of Weybridge Partners in Winchester, Ma to represent Pro2Kem in the USA. Val has extensive experience across a wide range of technologies and business activities helping both large and small companies successfully commercialise new technologies.

Speaking recently, Dr Livada said: "Pro2Kem is a wonderful example of an emerging company that is taking full advantage of trans-Atlantic growth opportunities. By combining the innovative skills of the biotech community in Scotland with the robust public and private entrepreneurial infrastructure in Massachusetts, Pro2Kem is positioning itself to rapidly access the large US customer base."

At the same time as establishing the office in Chelmsford, Pro2Kem have also reached agreement with the Polaris Division of Sippican Corp. in Marion, Ma to contract manufacture their current range of products at their state-of-the-art facility. Polaris currently provides a wide range of technology including FAA and FDA certified products globally. This will enable Polaris to develop a high quality, rapid turnaround, and low cost service to the global customer base.

https://www.chemeurope.com/en/news/38150/scottish-pro2kem-enters-us-market-from-their-new-base-in-chelmsford-massachusetts.html